Punchline at the end: " the Company wishes to info
Post# of 72440
Posted On: 10/30/2015 8:33:09 AM
Punchline at the end: " the Company wishes to inform shareholders that the documentation has been submitted to the U.S. Food and Drug Administration (FDA) requesting a meeting for Cellceutix's planned phase 2 trial of Kevetrin for ovarian cancer."
We'll be getting a lot more info when they get the trial design approved. We should be able to draw lots of conclusions about efficacy based on the trial design.
We'll be getting a lot more info when they get the trial design approved. We should be able to draw lots of conclusions about efficacy based on the trial design.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼